Top Markets
#1 Derive Derive +36.07%
#2 Cross Cross +18.56%
#3 The Bitcoin Bull The Bitcoin Bull +14.92%
#4 Geodnet Geodnet +10.04%
#5 Gama Token Gama Token +9.18%
#6 Biconomy Biconomy +8.72%
#7 Starpower Starpower +7.90%
#8 Humanity Humanity +7.57%
#9 Steakhouse ETH Morpho Vault Steakhouse ETH Morpho Vault +6.71%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +6.64%
Coin of the day
Derive Derive
Settings
Language
ENGLISH
Currency
USD
Theme
Kazia Therapeutics Limited Kazia Therapeutics Limited

Kazia Therapeutics Limited

KZA
Rank in Stocks #35840
Kazia Therapeutics Limited is a biotechnology firm specializing in oncology,... Kazia Therapeutics Limited is a biotechnology firm specializing in oncology, committed to developing innovative therapies for cancer. Its flagship product candidate, Paxalisib, is a brain-penetrant small molecule that inhibits the PI3K/Akt/mTor pathway and is currently being investigated as a potential treatment for glioblastoma. Additionally, the company is progressing EVT801, an investigational new drug aimed at combating various types of cancer. Established in 1994 and headquartered in Sydney, Australia, the entity was formerly known as Novogen Limited before adopting the name Kazia Therapeutics Limited in November 2017.
Share Price
$0.05207079
Last synced: 2023-11-15
Market Cap
$3.38M
Change (1 day)
0.13%
Change (1 year)
0.00%
Country
AU
Trade Kazia Therapeutics Limited (KZA)

Category

Healthcare
Earnings for Kazia Therapeutics Limited (KZA)
Earnings in 2026 TTM: 0
According to Kazia Therapeutics Limited latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Kazia Therapeutics Limited from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE